

# Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/GF92B0DB27C0EN.html>

Date: June 2022

Pages: 230

Price: US\$ 2,000.00 (Single User License)

ID: GF92B0DB27C0EN

## Abstracts

Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides comprehensive information

on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 21, 12, 2, 35 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Glomerulonephritis – Overview
- Glomerulonephritis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glomerulonephritis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glomerulonephritis – Companies Involved in Therapeutics Development
- Glomerulonephritis – Drug Profiles
- Glomerulonephritis – Dormant Projects
- Glomerulonephritis – Discontinued Products
- Glomerulonephritis – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Glomerulonephritis, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Target, 2022 (Contd..1)  
Number of Products by Stage and Target, 2022 (Contd..2)  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Glomerulonephritis – Pipeline by AKSO Biopharmaceutical Inc, 2022  
Glomerulonephritis – Pipeline by Alexion Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Algomedix Inc, 2022  
Glomerulonephritis – Pipeline by Alnylam Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Amyndas Pharmaceuticals LLC, 2022  
Glomerulonephritis – Pipeline by Anagenics Ltd, 2022  
Glomerulonephritis – Pipeline by Angion Biomedica Corp, 2022  
Glomerulonephritis – Pipeline by Apellis Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Argenx SE, 2022  
Glomerulonephritis – Pipeline by Arrowhead Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Bayer AG, 2022  
Glomerulonephritis – Pipeline by BioCryst Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Biogen Inc, 2022  
Glomerulonephritis – Pipeline by Boehringer Ingelheim International GmbH, 2022  
Glomerulonephritis – Pipeline by Cabaletta Bio Inc, 2022  
Glomerulonephritis – Pipeline by Calliditas Therapeutics AB, 2022  
Glomerulonephritis – Pipeline by Ceptur Therapeutics Inc, 2022  
Glomerulonephritis – Pipeline by Certa Therapeutics Pty Ltd, 2022  
Glomerulonephritis – Pipeline by ChemoCentryx Inc, 2022  
Glomerulonephritis – Pipeline by Chinook Therapeutics Inc, 2022  
Glomerulonephritis – Pipeline by Coegin Pharma AS, 2022  
Glomerulonephritis – Pipeline by Cytodesign Inc, 2022  
Glomerulonephritis – Pipeline by Delta 4 GmbH, 2022  
Glomerulonephritis – Pipeline by DiaMedica Therapeutics Inc, 2022

Glomerulonephritis – Pipeline by Dimerix Ltd, 2022  
Glomerulonephritis – Pipeline by Eledon Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Eli Lilly and Co, 2022  
Glomerulonephritis – Pipeline by Ergon Pharmaceuticals LLC, 2022  
Glomerulonephritis – Pipeline by Generian Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Goldfinch Bio Inc, 2022  
Glomerulonephritis – Pipeline by HanAll Biopharma Co Ltd, 2022  
Glomerulonephritis – Pipeline by Horizon Therapeutics Plc, 2022  
Glomerulonephritis – Pipeline by IGAN Biosciences Inc, 2022  
Glomerulonephritis – Pipeline by ImmunoWork LLC, 2022  
Glomerulonephritis – Pipeline by Inmagene Biopharmaceuticals Ltd, 2022  
Glomerulonephritis – Pipeline by InSilico Medicine, 2022  
Glomerulonephritis – Pipeline by Integral Molecular Inc, 2022  
Glomerulonephritis – Pipeline by INVENT Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Ionis Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022  
Glomerulonephritis – Pipeline by KeyMed Biosciences Inc, 2022  
Glomerulonephritis – Pipeline by Mallinckrodt Plc, 2022  
Glomerulonephritis – Pipeline by MorphoSys AG, 2022  
Glomerulonephritis – Pipeline by Novartis AG, 2022  
Glomerulonephritis – Pipeline by NovelMed Therapeutics Inc, 2022  
Glomerulonephritis – Pipeline by Oak Hill Bio Inc, 2022  
Glomerulonephritis – Pipeline by Omeros Corp, 2022  
Glomerulonephritis – Pipeline by Oraxion Therapeutics Inc, 2022  
Glomerulonephritis – Pipeline by Pfizer Inc, 2022  
Glomerulonephritis – Pipeline by PlateletBio, 2022  
Glomerulonephritis – Pipeline by Polyneuron Pharmaceuticals AG, 2022  
Glomerulonephritis – Pipeline by Puretech Health Plc, 2022  
Glomerulonephritis – Pipeline by Ra Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Reata Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by RemeGen Co Ltd, 2022  
Glomerulonephritis – Pipeline by River 3 Renal Corp, 2022  
Glomerulonephritis – Pipeline by Rohto Pharmaceutical Co Ltd, 2022  
Glomerulonephritis – Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022  
Glomerulonephritis – Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022  
Glomerulonephritis – Pipeline by Slate Bio Inc, 2022  
Glomerulonephritis – Pipeline by Sujana Biotech, LLC, 2022  
Glomerulonephritis – Pipeline by Surrozen Inc, 2022  
Glomerulonephritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Glomerulonephritis – Pipeline by Transcenta Holding Ltd, 2022  
Glomerulonephritis – Pipeline by Travers Therapeutics Inc, 2022  
Glomerulonephritis – Pipeline by Vera Therapeutics Inc, 2022  
Glomerulonephritis – Pipeline by Vertex Pharmaceuticals Inc, 2022  
Glomerulonephritis – Pipeline by Visterra Inc, 2022  
Glomerulonephritis – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022  
Glomerulonephritis – Pipeline by ZyVersa Therapeutics Inc, 2022  
Glomerulonephritis – Dormant Projects, 2022  
Glomerulonephritis – Dormant Projects, 2022 (Contd..2)  
Glomerulonephritis – Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Glomerulonephritis, 2022  
Number of Products under Development by Companies, 2022  
Number of Products by Top 10 Targets, 2022  
Number of Products by Stage and Top 10 Targets, 2022  
Number of Products by Top 10 Mechanism of Actions, 2022  
Number of Products by Stage and Top 10 Mechanism of Actions, 2022  
Number of Products by Routes of Administration, 2022  
Number of Products by Stage and Top 10 Routes of Administration, 2022  
Number of Products by Top 10 Molecule Types, 2022  
Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/GF92B0DB27C0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF92B0DB27C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

